As low as 
Many weight loss drugs from the past have yielded questionable results, but Semaglutide is a game changer for the future of weight management. Unlike some previous anti-obesity medications that primarily reduced the amount of dietary fat absorbed by the body, Semaglutide works through a different physiological pathway that targets hormones related to hunger and fullness.
 
Semaglutide mimics a hormone that prompts the pancreas to produce more insulin, which lowers blood sugar, reduces cravings, and slows down digestion. These mechanisms help individuals feel fuller on smaller portions and decrease the constant thoughts about food, often referred to as "food noise." Many patients who have taken Semaglutide report feeling satisfied with less food, which can lead to weight loss.
 
Additionally, Semaglutide may lower the risk of heart attacks and strokes. A recent study published in the New England Journal of Medicine found that in patients with obesity and heart failure, Semaglutide significantly reduced symptoms such as fatigue and shortness of breath. It also led to improvements in physical abilities and exercise performance.
 
Further research sponsored by the drug’s manufacturer, Novo Nordisk, indicated that Semaglutide reduced the risk of stroke and heart attack by 20% in individuals with obesity and a history of cardiovascular disease. While additional studies are necessary, these findings suggest that Semaglutide could potentially lower the risk of adverse cardiovascular events in certain high-risk populations.